Author

Kara‐Louise Royle

Observed names: K-L. Royle, Kara-Louise Royle, Royle, Kara-Louise

Institutions: University of Leeds, Cancer Research UK

Observed institutions: University of Leeds, Cancer Research UK, Cancer Research UK Clinical Trials Unit, Arthritis Research UK, Keele University

ORCID: 0000-0003-0225-1199

Observed ORCID: 0000-0003-0225-1199

OpenAlex ID: A5024897723

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

2019 · Gordon Cook, Kara-Louise Royle, et al. · The Lancet Haematology · 120

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

2023 · Janet E Brown, Kara-Louise Royle, et al. · The Lancet Oncology · 92

PDF

F railty-adjusted therapy i n T ransplant N on- E ligible patient s with newly diagno s ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

2022 · Amy Beth Coulson, Kara-Louise Royle, et al. · BMJ Open · 37

How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review

2023 · Kara-Louise Royle, David Meads, et al. · Trials · 31

PDF

Prognosis research ideally should measure time-varying predictors at their intended moment of use

2017 · Rebecca Whittle, Kara-Louise Royle, et al. · Diagnostic and Prognostic Research · 27

PDF

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study

2018 · Kara‐Louise Royle, Walter M. Gregory, et al. · British Journal of Haematology · 26

PDF

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT / UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

2019 · Gordon Cook, Kara‐Louise Royle, et al. · British Journal of Haematology · 20

PDF

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

2022 · Kara-Louise Royle, Amy Beth Coulson, et al. · BMJ Open · 18

PDF

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

2024 · Gordon Cook, Charlotte Pawlyn, et al. · Blood · 17

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

2023 · Gordon Cook, Charlotte Pawlyn, et al. · Blood · 13

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

2021 · Gordon Cook, Charlotte Pawlyn, et al. · Blood · 13

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

2019 · David Cairns, Charlotte Pawlyn, et al. · Blood · 13

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

2022 · Kwee Yong, Kara-Louise Royle, et al. · Blood · 7

Incorporation of Patient and Public Involvement in Statistical Methodology Research: Summary of Workshop Proceedings

2025 · Aiden Smith, Hannah Worboys, et al. · Statistics in Medicine · 5

PDF

The development and validation of prognostic models for overall survival in the presence of missing data in the training dataset: a strategy with a detailed example

2021 · Kara-Louise Royle, David A. Cairns · Diagnostic and Prognostic Research · 4

PDF

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

2023 · Karthik Ramasamy, David Allan Cairns, et al. · Blood · 3

Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study

2025 · Dipal Mehta, Robert Cicero, et al. · eJHaem · 2

PDF

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT

2024 · Fiona Collinson, Kara-Louise Royle, et al. · Health Technology Assessment · 2

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

2023 · Dipal Mehta, Laura Chiecchio, et al. · Blood · 2

LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)

2021 · J.E. Brown, K-L. Royle, et al. · Annals of Oncology · 2

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

2019 · Charlotte Pawlyn, Faith E. Davies, et al. · Blood · 2

Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.

2025 · Charlotte Pawlyn, Kara-Louise Royle, et al. · Blood · 1

How should overall survival be analysed in randomised clinical trials in cancer if participants receive subsequent treatment lines? A stakeholder consultation

2025 · Kara-Louise Royle, Peter Wheatstone, et al. · Trials · 1

PDF

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

2024 · Naser Ansari-Pour, Mohammad Kazeroun, et al. · Blood · 1

PDF

P-235 Isatuximab as Post-ASCT Therapy in MRDpositive Patients Augments CD8 Effector T Cell Differentiation: Insights from the UKMRA Phase 3 RADAR Study

2024 · Dipal Mehta, Jasmin Rahman, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Works count: 49

Citation count: 463

H-index: 12

I10-index: 12